CBOE · US Equities - Industry Sector · USA
The companies inside NURE trade 7% below what we estimate they are worth. We could give a verdict on 87% of the fund's weight: 30 holdings as reported to the SEC at 30 Jun 2026.
Where the money is: 22% in companies in the buy zone, 28% about fairly valued, 37% overvalued, 13% without a verdict.
The ten largest holdings, with our verdict on each:
Its expense ratio is 0.36% a year: on $10,000 held flat that is $360 over 10 years and $720 over 20.